CNS complications of breast cancer: Current and emerging treatment options

CNS Drugs

Volumn 21, Issue 7, 2007, Pages 559-579

  Kaal, Evert C A ^a   Vecht, Charles J ^a  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CARBAMAZEPINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EFAPROXIRAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; ETIRACETAM; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOTERIDOL; LACTATE DEHYDROGENASE; LAMOTRIGINE; METHOTREXATE; PHENYTOIN; PREDNISONE; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE;

ADVANCED CANCER; AGE DISTRIBUTION; BLOOD BRAIN BARRIER; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIOGRAPHY; BRAIN SURGERY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CAUDA EQUINA SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRANIAL NEUROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DRUG POTENTIATION; FOCAL EPILEPSY; GLIOBLASTOMA; HETEROZYGOTE; HUMAN; INTERMETHOD COMPARISON; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LUNG CANCER; MENINGEAL METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; PARAPLEGIA; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; RADIOSURGERY; REVIEW; RISK FACTOR; SEIZURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD DISEASE; SPINE METASTASIS; STEREOTAXIC SURGERY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; INCIDENCE; MENINGEAL NEOPLASMS; RISK FACTORS; SPINAL CORD NEOPLASMS;

EID: 34250890308     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721070-00003     Document Type: Review

References (130)

1. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003 Feb; 21 (1): 25-66
2. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981 Jul 15; 48 (2): 384-94
3. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993 Jun; 33 (6): 583-90
4. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990 Feb 22; 322 (8): 494-500
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001 Mar 15; 344 (11): 783-92
6. Lai R, Dang CT, Malkin MG, et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004 Aug 15; 101 (4): 810-6
7. Rogers LR. Cerebrovascular complications of cancer. Neurol Clin 2003; 21 (1): 167-92
8. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 May 23; 54 (10): 1886-93
9. Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993 Sep; 43 (9): 1678-83
10. Christiaans MH, Kelder JC, Arnoldus EP, et al. Prediction of intracranial metastases in cancer patients with headache. Cancer 2002 Apr 1; 94 (7): 2063-8
11. Herman MA, Tremont-Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol 2003 Jun; 26 (3): 273-9
12. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003 Jul 1; 21 (13): 2529-36
13. Regine WF, Scott C, Murray K, et al. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys 2001 Nov 1; 51 (3): 711-7
14. Rivas E, Sanchez-Herrero J, Alonso M, et al. Miliary brain metastases presenting as rapidly progressive dementia. Neuropathology 2005 Jun; 25 (2): 153-8
15. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004 Jul 15; 22 (14): 2865-72
16. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002 May 15; 94 (10): 2698-705
17. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983 Dec 15; 52 (12): 2349-54
18. Slimane K, Andre F, Delaloge S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004 Nov; 15 (11): 1640-4
19. Albiges L, Andre F, Balleyguier C, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol 2005 Nov; 16 (11): 1846-7
20. Ryberg M, Nielsen D, Osterlind K, et al. Predictors of central nervous system metastasis in patients with metastatic breast cancer: a competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005 Jun; 91 (3): 217-25
21. Evans AJ, James JJ, Cornford EJ, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004 Aug; 16 (5): 345-9
22. Boogerd W, Vos VW, Hart AA, et al. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 1993 Feb; 15 (2): 165-74
23. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991 Nov 11; 49 (5): 650-5
24. Marshall C, Blackburn E, Clark M, et al. Neuregulins 1-4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast. Breast Cancer Res Treat 2006; 96 (2): 163-8
25. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003 Jul; 14 (7): 1072-7
26. Myers RE, Johnston M, Pritchard K, et al. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001 May 15; 164 (10): 1439-44
27. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44 (3): 275-81
28. Yuh WT, Tali ET, Nguyen HD, et al. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995 Feb; 16 (2): 373-80
29. Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 1994 Jun; 15 (6): 1037-51
30. Van Dijk P, Sijens PE, Schmitz PI, et al. Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 1997; 15 (5): 535-41
31. Bukte Y, Paksoy Y, Genc E, et al. Role of diffusion-weighted MR in differential diagnosis of intracranial cystic lesions. Clin Radiol 2005 Mar; 60 (3): 375-83
32. Rees J. Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 2003 Dec; 16 (6): 643-50
33. Chiang IC, Kuo YT, Lu CY, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004 Aug; 46 (8): 619-27
34. Benard F, Turcotte E. Imaging in breast cancer: single-photon computed tomography and positron-emission tomography. Breast Cancer Res 2005; 7 (4): 153-62
35. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005 Mar; 90 (2): 105-12
36. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005 Apr; 184 (4): 1266-73
37. Abe K, Sasaki M, Kuwabara Y, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005 Oct; 19 (7): 573-9
38. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16mg per day. Neurology 1994 Apr; 44 (4): 675-80
39. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004 Dec; 79 (12): 1489-94
40. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003 Jul; 2 (7): 404-9
41. Wagner GL, Wilms EB, Van Donselaar CA, et al. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 2003; 12 (8): 585-6
42. Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 1971 Feb; 111 (2): 334-6
43. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996 Oct 1; 78 (7): 1470-6
44. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998 Nov 4; 280 (17): 1485-9
45. Boyd TS, Mehta MP. Stereotactic radiosurgery for brain metastases. Oncology (Huntingt) 1999 Oct; 13 (10): 1397-409
46. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004 May 22; 363 (9422): 1665-72
47. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986 Aug 15; 58 (4): 832-9
48. Boogerd W, Dalesio O, Bais EM, et al. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992 Feb 15; 69 (4): 972-80
49. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999 Apr 1; 85 (7): 1599-605
50. Cocconi G, Lottici R, Bisagni G, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990; 8 (3-4): 327-34
51. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000 Jul; 6 (7): 2585-97
52. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004 Jun 1; 10 (11): 3728-36
53. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 Mar 10; 352 (10): 987-96
54. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001 Jul; 53 (3): 259-65
55. Friedman HS, Evans B, Reardon D, et al. Phase II trial of temozolomide for patients with progressive brain metastases [abstract]. Proc Am Soc Clin Oncol 2003; 22: 102
56. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001 Feb; 12 (2): 249-54
57. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006 Jun; 17 (6): 952-6
58. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002 Sep 1; 20 (17): 3644-50
59. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005 Jan 1; 61 (1): 185-91
60. Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005 Jan; 71 (1): 61-5
61. Omuro AMP, Raizer JJ, Abrey LE. A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastasis [abstract]. J Clin Oncol 2004; 22 (14S): 1567
62. Caraglia M, Addeo R, Costanzo R, et al. Pegylated liposomal doxorubicin plus temozolomide in the salvage treatment of brain metastasis: the update [abstract]. J Clin Oncol 2004; 22 (14S): 1576
63. Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 2000 Jun; 21 (6): 1064-6
64. Pors H, von Eyben FE, Sorensen OS, et al. Longterm remission of multiple brain metastases with tamoxifen. J Neurooncol 1991 Apr; 10 (2): 173-7
65. van der Gaast A, Alexieva-Figusch J, Vecht C. Complete remission of a brain metastasis to third-line hormonal treatment with megestrol acetate. Am J Clin Oncol 1990 Dec; 13 (6): 507-9
66. Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J Neurooncol 1995; 24 (3): 299-301
67. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991 Feb 20; 83 (4): 288-91
68. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003 Feb 15; 21 (4): 588-92
69. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999 Aug; 17 (8): 2341-54
70. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002 Nov; 110 (9): 1309-18
71. Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995 Jul 15; 76 (2): 232-6
72. Crivellari D, Pagani O, Veronesi A, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001 Mar; 12 (3): 353-6
73. Schwonzen M, Kurbacher CM, Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000 Oct; 11 (9): 681-5
74. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998 Oct 29; 17 (17): 2235-49
75. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006 Feb 8; 232 (2): 123-38
76. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000 Jun; 18 (11): 2349-51
77. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 Jan 9; 235 (4785): 177-82
78. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 May 12; 244 (4905): 707-12
79. Littlejohns P. Trastuzumab for early breast cancer: evolution or revolution? Lancet Oncol 2006 Jan; 7 (1): 22-3
80. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003 Jun 15; 97 (12): 2972-7
81. Lower EE, Drosick DR, Blau R, et al. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003 Jun; 4 (2): 114-9
82. Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007 Jan; 18 (1): 23-8
83. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005 Mar; 20; 23 (9): 2114-6
84. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 Dec; 1 (2): 85-94
85. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006 Sep; 24 (25): 4107-15
86. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005 Aug 10; 23 (23): 5305-13
87. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11 (10): 1047-57
88. Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 1991 Jan; 20 (1): 53-8
89. Phillips TL, Scott CB, Leibel SA, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 1995 Sep 30; 33 (2): 339-48
90. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of gadolinium (III) texaphyrin complex: a new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994 Mar; 29 (3): 330-8
91. Sneed PK. Efaproxiral: should we hold our breath? J Clin Oncol 2006 Jan 1; 24 (1): 13-5
92. Hou H, Khan N, O'Hara JA, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: in vivo EPR oximetry study. Int J Radiat Oncol Biol Phys 2005 Apr 1; 61 (5): 1503-9
93. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006 Jan 1; 24 (1): 106-14
94. Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 2003 Jun 15; 21 (12): 2364-71
95. Stea B, Suh J, Shaw E, et al. Efaproxiral (EFAPROXYN) as an adjunct to whole brain radiation therapy for the treatment of brain metastases originating from breast cancer: updated survival results of the randomized REACH (RT-009) study [poster]. Proceedings of the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11; San Antonio. San Antonio (TX): Cancer Therapy & Research Center, 2005: 4064
96. US National Institutes of Health. Standard whole brain radiation therapy with supplemental oxygen, with or without concurrent RSR13 (efaproxiral), in women with brain metastases from breast cancer [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00083304?order=1 [Accessed 2007 May 29]
97. Maraveyas A, Sgouros J, Upadhyay S, et al. Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Br J Cancer 2005 Mar 14; 92 (5): 815-9
98. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003; 8 (5): 398-410
99. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983 Jul; 23 (3): 175-80
100. Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 1996 Oct; 7 (8): 773-86
101. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 2005; 23 (2): 145-54
102. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982 Feb 15; 49 (4): 759-72
103. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995 Jun 15; 75 (12): 2919-31
104. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975 Jul 24; 293 (4): 161-6
105. Chamberlain MC, Kormanik P, Howell SB, et al. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 1995 Sep; 52 (9): 912-7
106. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999 Nov; 5 (11): 3394-402
107. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993 Mar; 11 (3): 561-9
108. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987 Oct; 5 (10): 1655-62
109. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004 Dec; 40 (18): 2726-33
110. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997 Nov; 87 (5): 694-9
111. Costigan DA, Winkelman MD. Intramedullary spinal cord metastasis: a clinocopathological study of 13 cases. J Neurosurg 1985 Feb; 62 (2): 227-33
112. Schiff D, O'Neill BP. Intramedullary spinal cord metastases: clinical features and treatment outcome. Neurology 1996 Oct; 47 (4): 906-12
113. Mut M, Schiff D, Shaffrey ME. Metastasis to nervous system: spinal epidural and intramedullary metastases. J Neurooncol 2005 Oct; 75 (1): 43-56
114. Dunne JW, Harper CG, Pamphlett R. Intramedullary spinal cord metastases: a clinical and pathological study of nine cases. Q J Med 1986 Nov; 61 (235): 1003-20
115. Winkelman MD, Adelstein DJ, Karlins NL. Intramedullary spinal cord metastasis: diagnostic and therapeutic considerations. Arch Neurol 1987 May; 44 (5): 526-31
116. Gasser T, Sandalcioglu IE, Hamalawi BE, et al. Surgical treatment of intramedullary spinal cord metastases of systemic cancer: functional outcome and prognosis. J Neurooncol 2005 Jun; 73 (2): 163-8
117. Kalayci M, Cagavi F, Gul S, et al. Intramedullary spinal cord metastases: diagnosis and treatment: an illustrated review. Acta Neurochir (Wien) 2004 Dec; 146 (12): 1347-54
118. Constantini S, Miller DC, Allen JC, et al. Radical excision of intramedullary spinal cord tumors: surgical morbidity and long-term follow-up evaluation in 164 children and young adults. J Neurosurg 2000 Oct; 93 (2 Suppl.): 183-93
119. Hill ME, Richards MA, Gregory WM, et al. Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer 1993 Nov; 68 (5): 969-73
120. Fornasier VL, Horne JG. Metastases to the vertebral column. Cancer 1975 Aug; 36 (2): 590-4
121. Kim RY, Spencer SA, Meredith RF, et al. Extradural spinal cord compression: analysis of factors determining functional prognosis - prospective study. Radiology 1990 Jul; 176 (1): 279-82
122. Kienstra GE, Terwee CB, Dekker FW, et al. Prediction of spinal epidural metastases. Arch Neurol 2000 May; 57 (5): 690-5
123. Sorensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A (1): 22-7
124. Vecht CJ, Haaxma-Reiche H, van Putten WL, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989 Sep; 39 (9): 1255-7
125. Maranzano E, Latini P, Beneventi S, et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients: a phase II trial. Am J Clin Oncol 1996 Apr; 19 (2): 179-83
126. Greenberg HS, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol 1980 Oct; 8 (4): 361-6
127. Martenson Jr JA, Evans RG, Lie MR. Treatment outcome and complications in patients treated for malignant epidural spinal cord compression (SCC). J Neurooncol 1985; 3 (1): 77-84
128. Gerszten PC, Burton SA, Welch WC, et al. Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer 2005 Nov 15; 104 (10): 2244-54
129. Witham TF, Khavkin YA, Gallia GL, et al. Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol 2006 Feb; 2 (2): 87-94
130. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005 Aug 20; 366 (9486): 643-8